Attention-deficit/hyperactivity disorder: Cognitive evoked potential (P300) topography predicts treatment response to methylphenidate

Clinical Neurophysiology

Volumn 115, Issue 1, 2004, Pages 188-193

  Sangal, R Bart ^a   Sangal, Joanne M ^a  

^a Attention Disorders Institute   (United States)

Author keywords

Attention deficit hyperactivity disorder; Cognitive evoked potential (P300) topography; Methylphenidate

Indexed keywords

METHYLPHENIDATE;

AGE; ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; EVOKED AUDITORY RESPONSE; EVOKED VISUAL RESPONSE; FEMALE; HUMAN; HYPERACTIVITY; MALE; MEDICAL PARAMETERS; MULTICENTER STUDY; PARENT; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SINGLE BLIND PROCEDURE; SUSTAINED DRUG RELEASE; TOPOGRAPHY; TREATMENT OUTCOME;

EID: 0347990368     PISSN: 13882457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinph.2003.08.023     Document Type: Article

References (17)

1. Diagnostic and statistical manual of mental disorders. 4th ed. 1994;American Psychiatric Association, Washington, DC.
2. Biederman J. Sudden death in children treated with a tricyclic anti-depressant: a commentary. Biol Ther Psychiatry News. 14:1991;1-4.
3. Biederman J., Baldessarini R.J., Wright V., Knee D., Harmatz J.S. A double-blind placebo-controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry. 28:1989;777-784.
4. Binnie C.D., McGillivray B.B. Brain mapping - a useful tool or a dangerous toy? J Neurol Neurosurg Psychiatry. 2:1993;527-529.
5. Buitelaar J.K., Van Der Gaag R.J., Swaab-Barneveld H., Kuiper M. Prediction of clinical response to methylphenidate in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 34:1995;1025-1032.
6. DuPaul G.J., Power T.J., Anastopoulos A.D., Reid R. ADHD Rating Scale-IV. Checklist, norms, and clinical interpretations. 1998;Guilford Press, New York.
7. Faux S.F., McCarley R.W. Analysis of scalp voltage asymmetries using Hotelling's T2 methodology. Brain Topogr. 2:1990;237-245.
8. Jacobson N.S., Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. Journal of Consulting and Clinical Psychology. 59:1991;12-19.
9. Jacobson N.S., Folllette W.C., Revenstorf D. Toward a standard definition of clinically significant change. Behavior Therapy. 17:1984;308-311.
10. McGlinchey J.B., Jacobson N.S. Clinically significant but impractical? A response to Hageman and Arrindell. Behavior Research and Therapy. 37:1999;1211-1217.
11. Michelson D., Allen A.J., Busner J., Casat C., Dunn D., Kratochvil C., Newcorn J., Sallee F.R., Sangal R.B., Saylor K., West S., Kelsey D., Wernicke J., Trapp N.J., Harder D. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 159:2002;1896-1901.
12. Picton T.W. The P300 wave of the human event-related potential. J Clin Neurophysiol. 9:1992;456-479.
13. Sangal J.M., Sangal R.B., Persky B. Abnormal auditory P300 topography in attention deficit disorder predicts poor response to pemoline. Clin Electroenceph. 25:1995;204-213.
14. Sangal J.M., Sangal R.B., Persky B. Prolonged P300 latency in attention deficit hyperactivity disorder predicts poor response to imipramine. Clin Electroenceph. 27:1996;191-201.
15. Sangal R.B., Sangal J.M. P300 latency and age: a quadratic regression explains their relationship from age 5 to 85. Clin Electroenceph. 29:1998;1-6.
16. Sangal R.B., Sangal J.M. What is a significant response in drug studies of attention-deficit/hyperactivity disorder: statistical significance is necessary, but is it sufficient? Psychopharmacology Bulletin. 37:2003;50-58.
17. Sharbrough F., Chatrian G., Lesser R.P., Lüders H., Nuwer M., Picton T.W. Guidelines for standard electrode position nomenclature. 1990;American EEG Society, Bloomfield, CT.